LSE : 0IJO.L

Exelixis, Inc.

$55.45 USD

-$0.1 (-0.18%)

Volume
332
Average Volume
803
Market Capitalization
$14.78B
P/E Ratio
17.75
Dividend Yield
0.00%
Price Target
Year High
$56.57
Year Low
$17.42
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.26
Company Overview

LSE

Michael Morrissey

Biotechnology

Healthcare

0IJO.L

1077

US

USD

https://www.exelixis.com

650 837 7000

30161Q104

N/A

Liquidity Metrics

0.09

3.26

3.19

0.61

0.00

Sales & Valuation

$2.32B

5.86

7.39

15.19

3.55

Profitability

$2.78

$782.57M

35.08%

42.23%

40.21%

32.13%

P/E Metrics

17.75

0.45

0.45

Analyst Price Target & Rating

Buy

4/5

30 Analysts

%

Financial Health Scores

15.66

7/9

$837.66M

$2.59B

$657.84M

$970.08M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Patrick J. Haley Executive Vice President of Commercial
William Berg Senior Vice President of Medical Affairs
Stelios Papadopoulos Co-Founder & Independent Chair of the Board
Christopher J. Senner Executive Vice President & Chief Financial Officer
Deborah Burke Senior Vice President of Finance & Controller
Dana T. Aftab Executive Vice President of Research & Development
Stefan Krauss Vice President & Head of Business Development
Michael Morrissey Chief Executive Officer, President & Director
Brenda Hefti Senior VP & General Counsel
Andrew Ross Peters Senior Vice President of Strategy
Poll Results

No votes yet today — be the first to share your view!

About Exelixis, Inc. (LSE:0IJO.L) Stock

Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company markets several key medications. Its product portfolio includes CABOMETYX tablets, prescribed for patients with advanced renal cell carcinoma who have previously undergone anti-angiogenic therapy, and COMETRIQ capsules, utilized in the management of progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are derived from cabozantinib, a potent inhibitor targeting multiple tyrosine kinases, notably MET, AXL, RET, and VEGF receptors. Additionally, Exelixis provides COTELLIC, an MEK inhibitor employed as part of a combination regimen fo ... r advanced melanoma. In Japan, it offers MINNEBRO, an oral, non-steroidal selective blocker of the mineralocorticoid receptor, indicated for the treatment of hypertension. Its development pipeline features several promising candidates. These include XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases implicated in cancer growth and dissemination; XB002, an antibody-drug conjugate comprising a human monoclonal antibody against tissue factor (TF), currently being evaluated for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for advanced or metastatic solid tumors. Exelixis maintains a wide array of research collaborations and licensing agreements with numerous partners, such as Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. The company, originally known as Exelixis Pharmaceuticals, Inc., adopted its current name, Exelixis, Inc., in February 2000. Established in 1994, its corporate headquarters are situated in Alameda, California.

Frequently Asked Questions

What is the current Exelixis, Inc. (0IJO.L) stock price?

Exelixis, Inc.(LSE:0IJO.L) stock price is $55.45 in the last trading session. During the trading session, 0IJO.L stock reached the peak price of $56.57 while $17.4207 was the lowest point it dropped to. The percentage change in 0IJO.L stock occurred in the recent session was --0.18% while the dollar amount for the price change in 0IJO.L stock was -$0.1.

0IJO.L's industry and sector of operation?

The LSE listed 0IJO.L is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 0IJO.L?

Patrick J. Haley | Executive Vice President of Commercial
William Berg | Senior Vice President of Medical Affairs
Stelios Papadopoulos | Co-Founder & Independent Chair of the Board
Christopher J. Senner | Executive Vice President & Chief Financial Officer
Deborah Burke | Senior Vice President of Finance & Controller

How many employees does 0IJO.L have?

Number of 0IJO.L employees currently stands at 1077. 0IJO.L operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.

Link for 0IJO.L official website?

Official Website of 0IJO.L is: https://www.exelixis.com

How do I contact 0IJO.L?

0IJO.L could be contacted at phone #650 837 7000 and can also be accessed through its website. 0IJO.L operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.

How many shares of 0IJO.L are traded daily?

The average number of 0IJO.L shares traded daily for last 3 months was 803.

What is the market cap of 0IJO.L currently?

The market value of 0IJO.L currently stands at $14.78B with its latest stock price at $55.45